Catherine Williams

2.3k total citations
31 papers, 1.0k citations indexed

About

Catherine Williams is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Catherine Williams has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 13 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Catherine Williams's work include Multiple Myeloma Research and Treatments (17 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (7 papers). Catherine Williams is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (7 papers). Catherine Williams collaborates with scholars based in United Kingdom, United States and Germany. Catherine Williams's co-authors include Thierry Façon, David C. Linch, F. Geurs, Allan Lipton, Jean‐Paul Fermand, Donna Holloway, Philip R. Greipp, Pirow Bekker, Robert E. Coleman and Jean‐Luc Harousseau and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Catherine Williams

31 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Williams United Kingdom	15	556	540	497	155	128	31	1.0k
Amanda Farrugia Australia	9	659 1.2×	502 0.9×	306 0.6×	84 0.5×	65 0.5×	11	1.0k
P. Kostakis Australia	9	385 0.7×	437 0.8×	212 0.4×	91 0.6×	64 0.5×	11	842
Junling Zhuang China	13	268 0.5×	229 0.4×	311 0.6×	123 0.8×	48 0.4×	87	665
Karl Staser United States	19	332 0.6×	329 0.6×	211 0.4×	288 1.9×	63 0.5×	41	1.0k
Stephen B. Marley United Kingdom	16	281 0.5×	394 0.7×	384 0.8×	263 1.7×	37 0.3×	23	956
Trine Lindhardt Plesner Denmark	10	215 0.4×	213 0.4×	120 0.2×	201 1.3×	242 1.9×	30	655
Les Coulton United Kingdom	15	263 0.5×	292 0.5×	187 0.4×	40 0.3×	25 0.2×	22	761
R B Weiss United States	11	203 0.4×	225 0.4×	394 0.8×	144 0.9×	173 1.4×	13	855
Kyuhei Kohda Japan	9	196 0.4×	254 0.5×	407 0.8×	180 1.2×	99 0.8×	34	872
Monica Hecht Germany	12	353 0.6×	315 0.6×	297 0.6×	70 0.5×	36 0.3×	14	707

Countries citing papers authored by Catherine Williams

Since Specialization

Citations

This map shows the geographic impact of Catherine Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Williams more than expected).

Fields of papers citing papers by Catherine Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Williams. The network helps show where Catherine Williams may publish in the future.

Co-authorship network of co-authors of Catherine Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Williams. A scholar is included among the top collaborators of Catherine Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Williams. Catherine Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Walter, Jennifer K., Chris Feudtner, Aaron DeWitt, et al.. (2023). Parental communication satisfaction with the clinical team in the paediatric cardiac ICU. Cardiology in the Young. 34(2). 282–290. 2 indexed citations

2.

Yong, Kwee, Samantha Hinsley, Holger W. Auner, et al.. (2021). Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>). Haematologica. 106(10). 2694–2706. 8 indexed citations

3.

Gavazzi, Francesco, Catherine Williams, Justine Shults, et al.. (2021). Acquisition of Developmental Milestones in Hypomyelination With Atrophy of the Basal Ganglia and Cerebellum and Other TUBB4A-Related Leukoencephalopathy. Journal of Child Neurology. 36(10). 805–811. 1 indexed citations

4.

Cook, Mark, Michael A. Murphy, Kristian Bulluss, et al.. (2020). Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study. EClinicalMedicine. 22. 100326–100326. 37 indexed citations

5.

Pinto, Erin, Yoav Dori, Christopher L. Smith, et al.. (2020). Neonatal lymphatic flow disorders: impact of lymphatic imaging and interventions on outcomes. Journal of Perinatology. 41(3). 494–501. 21 indexed citations

6.

Yong, Kwee, Samantha Hinsley, Ruth M. de Tute, et al.. (2018). Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. Blood. 132(Supplement 1). 802–802. 6 indexed citations

7.

Leleu, Xavier, Evangelos Terpos, Ramón García‐Sánz, et al.. (2016). An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM). American Journal of Hematology. 91(8). 806–811. 9 indexed citations

8.

Dimopoulos, Meletios Α., David S. Siegel, Sagar Lonial, et al.. (2013). Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology. 14(11). 1129–1140. 181 indexed citations

9.

Popat, Rakesh, Heather Oakervee, Catherine Williams, et al.. (2009). Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. British Journal of Haematology. 144(6). 887–894. 37 indexed citations

10.

Österborg, Anders, Thomas J. Kipps, Jiřı́ Mayer, et al.. (2008). Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Blood. 112(11). 328–328. 35 indexed citations

11.

Popat, Rakesh, Catherine Williams, Mark Cook, et al.. (2007). Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.. Blood. 110(11). 2713–2713. 1 indexed citations

12.

D’Sa, Shirley, Kwee Yong, Chara Kyriakou, et al.. (2004). Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. British Journal of Haematology. 125(6). 756–765. 12 indexed citations

13.

Williams, Catherine, et al.. (2004). Combination Chemotherapy with Cyclophosphamide, Thalidomide and Dexamethasone Achieves a High Response Rate in Patients with Newly Diagnosed, VAD-Refractory and Relapsed Myeloma.. Blood. 104(11). 1499–1499. 6 indexed citations

14.

Peggs, Karl S., Stephen Mackinnon, Catherine Williams, et al.. (2003). Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biology of Blood and Marrow Transplantation. 9(4). 257–265. 72 indexed citations

15.

Shaw, Bronwen E., Karl S. Peggs, Jennifer M. Bird, et al.. (2003). The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. British Journal of Haematology. 123(5). 886–895. 19 indexed citations

16.

Body, Jean‐Jacques, Philip R. Greipp, Robert E. Coleman, et al.. (2003). A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 97(S3). 887–892. 295 indexed citations

17.

Peggs, Karl S., Stuart J. Ings, Panagiotis Kottaridis, et al.. (2000). Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring. Blood. 96(1). 369–371. 17 indexed citations

18.

Peggs, Karl S., Stuart J. Ings, Panagiotis Kottaridis, et al.. (2000). Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring. Blood. 96(1). 369–371. 14 indexed citations

19.

Pizzey, Arnold, et al.. (1998). p130, p107, and pRb Are Differentially Regulated in Proliferating Cells and during Cell Cycle Arrest by α-Interferon. Journal of Biological Chemistry. 273(37). 23659–23667. 47 indexed citations

20.

Williams, Catherine, David C. Linch, M J Watts, & N. Shaun B. Thomas. (1997). Characterization of Cell Cycle Status and E2F Complexes in Mobilized CD34+ Cells Before and After Cytokine Stimulation. Blood. 90(1). 194–203. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact